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Abstract. The effects of two luteinizing hormone releasing hormone analogues (a superagonist 
and an antagonist) on the conversion of testosterone to dihydrotestosterone in homogenates 
prepared from adult rat ventral prostates were studied. At higher doses, the superagonist 
showed a significant dose-dependent inhibition of the conversion of testosterone to 
dihydrotestosterone. In comparison, the antagonist showed only a marginally inhibitory 
trend. The implications of these observed effects vis-a-vis the use of the analogues in the 
endocrine  management  of  prostatic  cancer  have  been  discussed. 
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Introduction 
 
Since 1971, when Schally and associates elucidated the structure of naturally 
occurring luteinizing hormone releasing hormone (LHRH), numerous synthetic 
analogues have been developed, many of which have been found to have greatly 
increased potency compared to naturally occurring LHRH (Joseph and Smith, 1987). 
Chronic administration of pharmacologic doses of LHRH and its analogues has 
been demonstrated to inhibit steroidogenesis in a variety of species (Trachtenberg, 
1982). LHRH compounds, in combination with pure antiandrogen flutamide have 
been used in bringing about a hypoandrogenic state in patients with advanced stages 
of prostate cancer. However, a clear understanding of the effect of these compounds 
on the prostate still needs to be determined in order to confirm its use as a 
pharmacologic agent of castration. In this context steroidogenic conversions in the 
prostate, mainly conversion of testosterone to dihydrotestosterone, would be of 
importance since DHT has been found to be a useful marker for antiandrogen 
therapy in prostate cancer (Geller et αl., 1984). No studies have so far been available 
on this aspect. A preliminary study carried out by us using a synthetic LHRH 
demonstrated some increase in the in vitro conversion of testosterone to DHT in 
immature rat ventral prostates. This change was however not significant (Sheth et al., 
1987b). It was interesting therefore to extend the study to LHRH analogues in order 
to gain insight into the interaction of these compounds with steroidogenic 
 
 
†To  whom  all  correspondence  should  be  addressed. 
Abbreviations  used:  LHRH,  Luteinizing  hormone  releasing  hormone;  DHT,  dihydrotestosterone. 
 
105 
106 Maitra  et  al. 
 
conversions in the prostate. This paper describes studies with two such LHRH 
analogues. 
 
Materials  and  methods 
 
Seventy five day old male rats of Holtzman strain were used. The ventral prostates 
of these rats were excised under ether anaesthesia and processed as described by 
Sheth et al. (1987a). However, instead of using minced prostate tissue, the prostates 
were pooled and homogenized such that 1 ml of the homogenate contained 40 mg of 
the prostate tissue. Conversion of testosterone in vitro in the presence of NADPH 
was carried out using 1 ml of homogenate in each tube. The procedures involving in 
vitro conversion, extraction, separation and quantitation of 5 α-reductase activity 
have  been  described  in  detail  earlier  (Joseph  et  al.,  1987;  Sheth  et al., 1987a). 
Using this method we determined the effect of OvurelinR a gonadotropin releasing 
hormone superagonist, and HB235, an LHRH inhibitor, on the 5 a-reductase activity
from mature rat prostates. As before, the results are described in terms of the amount 
of  testosterone  reduced  to  its  major  metabolite,  DHT. 
The validity criteria employed to validate the method have been fully described 
earlier (Sheth  et  al., 1987a). 
 
Results 
 
Table 1 presents data indicating 5 α-reductase activity obtained in the presence of 4 
different doses of the superagonist Ovurelin and in the absence of this compound 
(control). At the lower doses used (25 and 50 ng) no significant changes were 
observed compared to the control either in the amount of testosterone reduced or in 
percentage conversion. However, at higher doses (75 and 250 ng), both parameters 
showed a clear declining trend. At 250 ng, the decrease was significant with respect to 
the control as well as the 25 and 50 ng doses. At 75 ng the amount 
Table 1. Effect of LHRH superagonist (Ovurelin) on testosterone metabolism in mature 
of testosterone 
 
rat  ventral  prostate  in  vitro. 
 
All values are mean ± S E of mean. 
Figures in parentheses indicate the number of determinations. 
a  Significantly lower than control (Ρ < 0·05). 
b Significantly lower than 25 ng (Ρ < 0·05). 
c  Significantly lower than control (P < 0·05); 25 ng(P <0·05). 
d  Significantly lower than control (P < 0·05); 25 ng (P <0·05); 50 ng ( P <0·05). 
e  Significantly lower than control (Ρ < 0·01); 25 ng (P <0·05); 50 ng (P <0·001). 
f  Significantly lower than, control (P < 0·01); 75 ng (P <005). 
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reduced was significantly lower compared to that at 25 ng whereas the percentage 
reduction was significantly lower with respect to the control as well as the 25 ng dose. 
Thus the results clearly establish a dose-dependent inhibitory effect of Ovurelin on 
reduction of testosterone. The DHT/testosterone ratios also confirm this inhibitory 
effect. The maximum decrease in this ratio was observed at the highest dose (250 ng). 
At 50 ng also the decrease was significant with respect to the control; at other doses 
it  was  less  significant. 
The LHRH antagonist HB235 did not cause any significant change with respect to 
the control either in the amount of testosterone reduced or in the percentage 
conversion (table 2). However, the DHT/testosterone ratios do indicate an inhibition 
of the conversion of testosterone to DHT at higher doses (75 and 250 ng).
 
 
Table 2. Effect of LHRH antagonist (HB235) on testosterone metabolism in mature rat 
ventral  prostate  in  vitro. 
 
All values are mean ± S E of mean. 
Figures in parentheses indicate the number of determinations. 
a Significantly lower than 25 ng (P <0·05); 50 ng (Ρ < 0·05). 
b,c Significantly lower than 50 ng (Ρ <0·05). 
d Significantly lower than control (P <0·05); 25 ng (Ρ<0·001); 50 ng (P<0·001). 
 
 
Thus a comparison of the two analogues tested shows that the superagonist has a 
significant dose-dependent inhibitory effect on the 5 α-reductase activity at higher 
doses;  the  effect  of  the  antagonist  is  relatively  marginal. 
 
Discussion 
 
The methodology adopted in the present study is based on the major assumption 
that in rat prostate tissue more than 90% of testosterone is converted to DHT. This 
has been previously demonstrated under different experimental conditions by Massa 
and Martini (1974) and later confirmed by Purvis et al. (1986). The results obtained 
in our previous study with LHRH using immature rat prostates did not show any 
significant changes although a trend towards augmentation of the 5 α-reductase 
activity was perceptible. In this context, it is interesting to observe that both the 
LHRH analogues tested in the present study showed an inhibitory effect on the in 
vitro conversion of testosterone to DHT in mature rat prostate tissue homogenate, 
although the extent of inhibition varied greatly. The agonist showed a predominantly 
greater inhibition of the 5 α-reductase activity than the antagonist under similar 
conditions. 
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Levels of DHT, which is the major androgen in prostate tissue, have been used as 
an indicator of the adequacy of antiandrogen therapy in prostate cancer (Geller et αl., 
1979). As stated by these authors, the potential usefulness of any antiandrogenic agent 
would be determined by the DHT levels in prostate tissue. The level of DHT would 
depend upon the following factors—plasma testosterone substrate, 5 α-reductase, 3- 
oxidoreductase and receptor binding, all essential biochemical steps for the 
mediation of androgen action. Therefore inhibition of the 5 α-reductase activity 
observed in our study is interesting, since it would lead to a decline in the tissue 
DHT store. However, to obtain any conclusive evidence, the other factors mentioned 
above also need to be investigated. Studies on the effect of LHRH analogues on 
steroidogenic enzymes in the testis have been extensively carried out but such studies 
(for the prostate) are few. Using the agonistic analogue Buserelin, Trachtenberg 
(1982) demonstrated that in spite of 90% reduction in serum androgen concentration, 
prostatic weight and prostatic androgen receptor content remained largely 
unchanged. Detailed studies on similar lines need to be carried out using Ovurelin 
and  HB  235  in  order  to  determine  their  potential  in prostate cancer  therapy. 
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